Business Context and Reporting Period
Company: Exicure, Inc. (XCUR)
Filing Type: Form 8-K (Current Report)
Date: December 11, 2019
Event: Update on Phase 1b/2 clinical trial for AST-008, an investigational spherical nucleic acid (SNA) TLR9 agonist for immuno-oncology, evaluated alone and in combination with pembrolizumab in patients with solid tumors.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding clinical trial updates and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
- Study Status: Fourteen patients have been enrolled and dosed. The fifth and final dose escalation cohort is open and enrolling.
- Safety Profile: No treatment-related serious adverse events or dose-limiting toxicities have been observed.
- Patient Demographics: Enrollment includes 5 melanoma, 4 Merkel cell carcinoma (MCC), 2 cutaneous squamous cell carcinoma, 2 head and neck squamous cell carcinoma, and 1 mucosal melanoma patient. Most had progressive disease on prior anti-PD-(L)1 therapy.
- Biomarker Data: AST-008 administration produced cytokine/chemokine expression and immune cell activation indicative of desired immune activation.
- Efficacy in MCC:
- One patient with prior progression on anti-PD-1 therapy achieved confirmed stable disease with decreased target lesion diameters for over 12 weeks.
- One patient experienced a target lesion complete response and a confirmed overall partial response lasting longer than 24 weeks.
- Other Outcomes: Nine patients had progressive disease; two are unevaluated; one is not evaluable.
Guidance, Outlook, and Risks
Outlook: Based on positive biomarker data and initial tumor responses, the Company anticipates enrolling MCC patients who have previously failed anti-PD-1/PD-L1 therapy into its Phase 2 study during the first quarter of 2020. Detailed results are expected at upcoming oncology meetings.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include unexpected costs reducing cash runway, failure of clinical programs to advance or result in approved products, cost and timing of trials, patient enrollment challenges, safety/efficacy concerns, regulatory developments, and intellectual property protection.
Investor Verification Checklist
- Verify the timeline for the Phase 2 study enrollment in Q1 2020.
- Monitor upcoming presentations at major oncology meetings for detailed efficacy and safety data.
- Review the Company's most recent 10-K or 10-Q filings for current cash runway and liquidity status, as this 8-K does not provide financial data.
- Assess the durability of the partial response observed in the MCC patient (reported as >24 weeks).